Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc - 1 May 2010

Vranic Semir, Tawfik Ossama, Palazzo Juan, Bilalovic Nurija, Eyzaguirre Eduardo, Lee Lisa Mj, Adegboyega Patrick, Hagenkord Jill, Gatalica Zoran

Abstract excerpt

This study was undertaken to investigate epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER-2)/neu expression in a cohort of apocrine carcinomas of the breast with emphasis on the classification of the breast tumors with apocrine morphology. In total, 55 breast carcinomas morphologically diagnosed as apocrine were evaluated for the steroid receptor expression profile...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Ductal, Breast
Share to Epidermal Growth Factor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Neoplastic

Share to Immunohistochemistry

Share to In Situ Hybridization, Fluorescence

Share to Receptor, ErbB-2

Share to Receptors, Steroid

Share to Statistics, Nonparametric

Source

Identifiers

PMID: 20208479
DOI: 10.1038/modpathol.2010.50

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast.PMID 20208479Read ↗

Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast.Semantic proximity Read ↗

Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas.Semantic proximity Read ↗

HER2-positive Apocrine Carcinoma of the Breast: A population-based Analysis of Treatment and OutcomeSemantic proximity Read ↗

Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ.Semantic proximity Read ↗

Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.Semantic proximity Read ↗

Neoadjuvant Chemotherapy Response in Triple-Negative Apocrine Carcinoma: Comparing Apocrine Morphology, Androgen Receptor, and Immune Phenotypes.Semantic proximity Read ↗

Relationship between androgen receptor and androgen receptor-related protein expression in breast cancers focusing on morphologically identified carcinoma with apocrine differentiationSemantic proximity Read ↗

Identification of molecular apocrine breast tumours by microarray analysis.Semantic proximity Read ↗

PIK3CA mutation in ER-negative and HER2-positive breast cancer with apocrine differentiation.Semantic proximity Read ↗

A Feedback Loop between Androgen Receptor and ERK Signaling in Estrogen Receptor-Negative Breast CancerSemantic proximity Read ↗

Update on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studiesSemantic proximity Read ↗

Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.